Celgene, page-10

  1. 3,053 Posts.
    lightbulb Created with Sketch. 2
    never personal? How come you gave thumbs up to some pretty vile posts questioning my sex life with my wife if it's not personal for you? Your cognitive dissonance doesn't appear to be limited to your investment choices!

    I think most owners of MSB stock would be overjoyed at the concept of bid for the company - it would at least mean that someone thought it had some value. However it is vanishingly unlikely, and not because the register is tied up as some seem to suggest - Silviu and Thorney only control ~22% now, and given Teva's withdrawal from the CHF funding agreement and Cephalon's obvious lack of interest in partnering with MSB, it's highly likely that a strategic buyer could acquire a ~20% stake very quickly.

    No, it is vanishingly unlikely because it seems most major players in the stem cell space have taken a look at MSB at some time and then walked, whilst many of the majors have withdrawn entirely from stem cells Sanofi and Pfizer have both exited partnerships, whilst Osiris sold their stem cell assets to the highest bidder for $50m - that bidder was MSB!!

    Combine that with Teva walking from the CHF trial after the early readout on efficacy and what do you have left? A massive funding requirement for products with highly questionable efficacy, and it still has a market cap approaching half a billion. Crazy!
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$2.31
Change
-0.100(4.15%)
Mkt cap ! $2.956B
Open High Low Value Volume
$2.33 $2.35 $2.15 $30.94M 13.57M

Buyers (Bids)

No. Vol. Price($)
5 75954 $2.30
 

Sellers (Offers)

Price($) Vol. No.
$2.32 10350 2
View Market Depth
Last trade - 16.17pm 21/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.